

CPIC (SH601601, HK02601)
Stock Data (ending Feb. 28, 2019)

| | |
|--------------------------------|-------------|
| Total equity base (in million) | 9,062 |
| A-share | 6,287 |
| H-share | 2,775 |
| Total Cap (in RMB million) | 283,805 |
| A-share | 213,883 |
| H-share (in HKD million) | 82,001 |
| 6-mth highest/lowest | |
| A-share (in RMB) | 33.09/27.33 |
| H-share (in HKD) | 28.90/24.60 |

IR Calendar

March 26, 2019

2018 Annual Results Announcement

Shanghai / Hong Kong

Contents
● Company Updates

CPIC P/C and CPIC Allianz Health improve product supply based on customer segmentation

Regulator releases results for 2018 Q4 Comprehensive Risk Rating

Investor Relations Department

Tel: 021-58767282

Fax: 021-68870791

E-MAIL: ir@cpic.com.cn

Add: 40F, 190 Central Yincheng Rd.,

Shanghai, P.R. China, 200120

Contact: Gong Zheng

Tel: 021-33968661

E-MAIL: gongzheng-001@cpic.com.cn

Tel: 021-58767282

Disclaimer:

China Pacific Insurance Company (the "Company") abides by the disclosure obligations by securities regulators and stock exchanges in accordance with the law. The newsletter is for information purpose only and do not constitute investment suggestion in any circumstances. The Company nor has any liability for any loss howsoever arising from any information contained in the newsletter. All copyrights are reserved by the Company. The newsletter belongs to non-public information. Without written authorization by the Company, none part of the newsletter could be copied or substituted to others in any circumstance

Premium Income (Unit: in RMB million)

| | Jan. -Feb. | Changes | Feb. | Changes |
|----------------|---------------|---------------|---------------|---------------|
| P&C | 22,701 | 32.75% | 7,318 | 19.63% |
| Life | 66,795 | 24.56% | 15,150 | 14.03% |

Company Updates

- **CPIC P/C and CPIC Allianz Health improve product supply based on customer segmentation**

Recently, CPIC P/C and CPIC Allianz Health, two subsidiaries of CPIC Group, jointly launched *Yue Xiangbao*, a medical product tailor-made for the middle-aged and the elderly people. It is a plan for cancer protection with value-added services. It not only covers malignant tumour, but also minor illnesses like in-situ cancer, with limits on the insured further relaxed to between 45-80, with renewals to 100 years. Maximum sum assured reaches RMB2 million, spanning a wide range of medical expenses such as hospitalization, special out-patient and first-aid.

Patients of chronic illnesses like high blood pressure or diabetes can also take out this product, which may be bundled with certain high-end treatment procedures including proton & heavy ion radiation, as well as value-added services such as “green channels” for critical illnesses, genetic testing for targeting anti-cancer drugs.

In the meantime, CPIC P/C also brought to market a health insurance product customized for women, the first of its kind in its history, marking another step in its effort to develop products based on customer segmentation. The plan covers the age cohort of 18 and 65, renewable to 100 years, providing protection against in-situ cancer or malignant tumour in breasts, uterus, uterine neck, ovary, ovarian ducts, as well as SLE and kidney diseases.

- **Regulator releases results for 2018 Q4 Comprehensive Risk Rating**

CBIRC released results for the Comprehensive Risk Rating for Q4 of 2018. CPIC Group and its subsidiaries all did well, with the life, health and agricultural subsidiaries rated A, and the property and casualty B for the 4th consecutive quarter of 2018.